Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes
BIOLOGICAL
2 trials
Sponsors
National Cancer Institute (NCI)
Conditions
Melanoma
Metastatic Melanoma
Skin Cancer
Phase 2
Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma
Terminated
NCT00612222
National Cancer Institute (NCI)
Metastatic Melanoma, Skin Cancer
Start: 2008-01-31
End: 2011-03-31
Updated: 2015-10-28
Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients
Terminated
NCT00706992
National Cancer Institute (NCI)
Melanoma
Start: 2008-06-30
End: 2012-11-30
Updated: 2015-10-28